Manch-based Boston Therapeutics closes $5.3M placement of common stock, warrants
Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes.
LATEST NEW HAMPSHIRE ANGLE
Lawyer for alleged Lt. Col. charged with sex trafficking was just working on his War College thesis
Unions endorse pipeline through NH